ClinicalTrials.gg
Sign In

Graft vs Host Disease clinical trials

The registry lists 804 studies for Graft vs Host Disease across more than 10 countries. 149 are recruiting or about to start. 552 of them are mainly about Graft vs Host Disease (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its narrower condition Bronchiolitis Obliterans Syndrome too: 1,472 studies, 264 open.

ClinicalTrials.gov finds 1,701 studies for Graft vs Host Disease. How that becomes 804 here

This page counts the studies the registry files under Graft vs Host Disease, and those it files under no condition that list Graft vs Host Diseasethemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 1,701Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −667Filed under a narrower condition, counted on its own pageBronchiolitis Obliterans Syndrome 661
  3. −21List Graft vs Host Disease as a condition, but the registry did not file them under itMost often written as “Acute Graft Versus Host Disease” (4), “Graft Versus Host Disease in Eye” (4), and “Ocular Graft vs Host Disease” (2). The registry filed them under other conditions only, most often Dry Eye Syndromes (6) and Hematologic Neoplasms (5).
  4. −209Match it another way186 name it in the title, 11 in a keyword, and 12 by a synonym or other text the search reads.
  5. 804The count on this page110 of them list Graft vs Host Disease in their own words; the registry filed them under no condition.

Get an email when these change. Save the Graft vs Host Disease studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
374
Terminated
113
Recruiting
103
Status unknown
86
Active, not recruiting
38
Not yet recruiting
36

Phase

Phase 2
375
Phase 1
208
Phase 3
97
Phase 4
24
Early Phase 1
15

Where

United States
454
China
81
France
54
Italy
53
Germany
53
Canada
40

Who runs them

National Heart, Lung, and Blood Institute (NHLBI) (28) · Fred Hutchinson Cancer Center (25) · M.D. Anderson Cancer Center (23) · Dana-Farber Cancer Institute (21) · National Cancer Institute (NCI) (15) · H. Lee Moffitt Cancer Center and Research Institute (14) · Incyte Corporation (12) · Peking University People's Hospital (12)

What is being tested here

Drugs under test in Graft vs Host Disease studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Cyclophosphamide12648
Ruxolitinib11423
Abatacept4010
Tacrolimus3436
Sirolimus2635
Fludarabine2122
Methotrexate2522
Mycophenolic Acid2422
Busulfan2116
Melphalan2010

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 15 open · Alkylating agents 14 open · JAK inhibitors 14 open · Antimetabolites 4 open · Calcineurin inhibitors 3 open

Coming up

19phase 3 studies under way
46studies finish main data collection within a year4 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 103 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 42 (41%) stop at 75 or younger. 42 (41%) take children under 18. 1 (1%) are for women only and 0 (0%) for men only; 9 (9%) take healthy volunteers.

Recruiting studies that take each age, of 103
AgeWomenMen
1030 (29%)30 (29%)
1899 (96%)98 (95%)
3096 (93%)95 (92%)
4095 (92%)94 (91%)
5095 (92%)94 (91%)
6590 (87%)89 (86%)
7570 (68%)70 (68%)
8559 (57%)59 (57%)

Across all 804 studies, recruiting or not: 43% stop at 75 or younger and 26% at 65; 42% take children; <1% are for women only and <1% for men only; 6% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Graft vs Host Disease studies take

Of 102 phase 2 interventional studies under Graft vs Host Disease, half reached primary completion within 51 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 147 mo24–65 · 49 studies—49 mo28–69 · 39 studies
Phase 1/255 mo35–76 · 39 studies——
Phase 251 mo29–87 · 102 studies—55 mo36–116 · 85 studies
Phase 334 mo24–48 · 31 studies——
Interventional, no phase41 mo23–89 · 32 studies——
Observational60 mo37–154 · 46 studies—60 mo38–154 · 45 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 14, 2026.

Started recruiting5

Stopped1

Newly registered1

Studies

Recruiting first, then most recently updated. Showing 50 of 804. Browse all 804 → or search them.